Review of the development and approval of Xiannuoxin, the first domestic anti-COVID-19 drug targeting the 3C-like protease (3CLpro) approved in China. Xiannuoxin was jointly developed by Simcere Pharmaceutical Group, Shanghai Institute of Materia Medica, and the Wuhan Institute of Virology. The drug combines simnotrelvir and ritonavir in one package. The development and approval process took 14 months, and phase 2/3 trials showed Xiannuoxin can effectively shorten the disease course and rapidly reduce viral load in mild-moderate COVID-19 patients.
See Bischof et al. for another review covering xiannuoxin for COVID-19.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Vaccines and treatments are complementary. All practical, effective, and safe
means should be used based on risk/benefit analysis. No treatment, vaccine, or
intervention is 100% available and effective for all current and future
variants. We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.